# Radiopharmaceutical Theranostics Market > Radiopharmaceutical Theranostics Market Research Report: Size, Share, Trend Analysis By Applications (Oncology, Cardiology, Neurology, Endocrinology), By Radioisotope (Fluorine-18 (18F), Carbon-11 (11C), Nitrogen-13 (13N), Gallium-68 (68Ga), By Modality (PET (Positron Emission Tomography), SPECT (Single-Photon Emission Computed Tomography), SPECT/CT (Single-Photon Emission Computed Tomography/Computed Tomography), PET/CT (Positron Emission Tomography/Computed Tomography), By Target Disease (Cancer, Cardiovascular Disease, Neurological Disorders, Endocrine Disorders) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.85% - **2024:** $ 2.11 Billion - **2025:** $ 2.26 Billion - **2035:** $ 4.37 Billion - **Key Players:** Companies such as Novartis (CH), Bayer (DE), GE Healthcare (GB), Siemens Healthineers (DE), Lantheus Medical Imaging (US), Bracco Imaging (IT), Elekta (SE), Telix Pharmaceuticals (AU), Iradimed Corporation (US) are some of the major participants in the global market. **Report ID:** MRFR/HC/25439-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 08, 2026 **URL:** https://www.marketresearchfuture.com/reports/radiopharmaceutical-theranostics-market-27107 --- ## Market Summary ## **Global****Radiopharmaceutical Theranostics Market Overview:** As per MRFR analysis, the Radiopharmaceutical Theranostics Market Size was estimated at 1.94 (USD Billion) in 2023. The Radiopharmaceutical Theranostics Market Industry is expected to grow from 2.11 (USD Billion) in 2024 to 3.83 (USD Billion) by 2032. The Market CAGR (growth rate) is expected to be around 6.85% during the forecast period (2024 - 2032). ### **Key Radiopharmaceutical Theranostics Market Trends Highlighted** Key market drivers for radiopharmaceutical theranostics include the increasing prevalence of cancer and other diseases, rising demand for personalized medicine, and technological advancements. Opportunities for growth lie in the exploration of new theranostic agents, targeting unmet medical needs, and expanding into emerging markets.Recent trends in radiopharmaceutical theranostics include the development of targeted radiopharmaceuticals, the integration of artificial intelligence and machine learning, and the increasing adoption of theranostics in clinical practice. These advancements are expected to improve the accuracy, efficacy, and accessibility of radiopharmaceutical theranostics in the future. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Radiopharmaceutical Theranostics Market Drivers** ### **Rising Prevalence of Chronic Diseases** One of the key drivers of the Global Radiopharmaceutical Theranostics Market Industry is the increasing prevalence of chronic diseases, such as cancer and cardiovascular diseases. With the population aging and living longer, it is likely that the incidence of such diseases will continue to increase in the future. As a result, the market for radiopharmaceutical theranostics will also grow, as they can be used to diagnose and treat such diseases. They have several key features that make them preferred to traditional medical imaging and treatment methods.First, they can be used to locate and follow the movement of specific cells and tissues in the body. They are also able to detect very small amounts of these and can identify their precise location. Moreover, they can also be used to concentrate in a certain area so as to deliver a dose of radiation for therapeutic or research purposes. That being said, radiopharmaceutical theranostics are used increasingly to manage various chronic diseases. ### **Technological Advancements** Technological advancements are driving the Global Radiopharmaceutical Theranostics Market Industry. The technological advancements include the development of new radiopharmaceuticals, new imaging techniques, and new delivery systems. These advancements are making radiopharmaceutical theranostics more effective, more convenient, and more accessible. For example, the development of new radiopharmaceuticals with improved targeting capabilities makes it possible to diagnose and treat diseases more precisely.The development of new imaging techniques, such as PET/CT and SPECT/CT, makes it possible to get more detailed images of the body, which can help to improve diagnosis and treatment planning. The development of new delivery systems, such as nanocarriers and liposomes, makes it possible to deliver radiopharmaceuticals to particular cells and tissues more efficiently. ### **Government Support** Government support is another key driver of the global radiopharmaceutical theranostics market industry. Across the globe, governmental bodies are gradually acknowledging the potential of radiopharmaceutical theranostics for improving patient care and reducing healthcare costs. Thus, they provide funds for research and development, as well as implement policies to support the use of radiopharmaceutical theranostics in practice. For example, the U.S. Government has provided funds for the development of new radiopharmaceuticals and imaging technologies through the National Institutes of Health. The European Union ensconced its support for radiopharmaceutical theranostics within the Horizon 2020 program, a rather massive research and innovation program designed to last from 2014 to 2020. ## **Radiopharmaceutical Theranostics Market Segment Insights:** ### **Radiopharmaceutical Theranostics Market Application Insights** The Global Radiopharmaceutical Theranostics Market is segmented by application and major segments include oncology, cardiology, neurology and endocrinology. The largest share of the market is attributed to the increasing number of cancer cases, as well as a growing need for personal and targeted treatment. Another segment, cardiology, is expected to experience substantial growth in the radiopharmaceutical theranostics market in the period of 2023-2032. Such growth is associated with the rapidly increasing incidence of cardiovascular conditions as well as a growing number of theranostics procedures for determining the severity of diseases and the most appropriate medication.Another segment, neurology, is predicted to grow at a decent pace, with an increasing number of new theranostics at an early detection development stage. Additionally, the need for theranostics is growing exponentially, as the number of people with neurological conditions is also on the rise now. The last segment, cardiology, is also expected to experience regular growth, with the growing use of theranostics in the management of endocrine-related conditions, such as diabetes and thyroid issues. Future growth will be facilitated by a better understanding of theranostics and an increased awareness of the need for personalized treatment. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Radiopharmaceutical Theranostics Market Radioisotope Insights** Radioisotope Segment Insights and Overview The radioisotope segment of the global radiopharmaceutical theranostics market is expected to grow significantly in the coming years, driven by the increasing demand for personalized medicine and the development of new radioisotope-based therapies. Among the key radioisotopes used in theranostics, Fluorine-18 (18F), Carbon-11 (11C), Nitrogen-13 (13N) and Gallium-68 (68Ga) hold significant market share. Fluorine-18 (18F): 18F is the most widely used radioisotope in theranostics due to its short half-life (110 minutes) and versatile chemistry, allowing for the synthesis of a wide range of radiopharmaceuticals.It is commonly used in positron emission tomography (PET) imaging for cancer diagnosis and staging. Carbon-11 (11C): 11C has a short half-life of 20 minutes, making it suitable for imaging applications where rapid clearance is desired. It is primarily used in PET imaging for neurology and cardiology applications, including the assessment of cerebral blood flow and myocardial perfusion. Nitrogen-13 (13N): 13N has a half-life of 10 minutes and is commonly used in PET imaging for the assessment of lung function and ventilation. It is also used in the development of radiopharmaceuticals for cancer therapy.Gallium-68 (68Ga): 68Ga has a half-life of 68 minutes and is widely used in PET imaging for the detection and localization of tumors, as well as in the development of theranostic radiopharmaceuticals for targeted cancer therapy. The growth of the radioisotope segment is attributed to the increasing adoption of theranostic approaches in various therapeutic areas, including [oncology](../../../reports/oncology-information-systems-market-7080), neurology, and cardiology. The development of new radioisotope-based therapies, such as targeted alpha therapy (TAT) and radionuclide therapy, is also driving the demand for radioisotopes in the theranostics market. ### **Radiopharmaceutical Theranostics Market Modality Insights** The Modality segment of the Global Radiopharmaceutical Theranostics Market is expected to witness significant growth over the forecast period. PET (Positron Emission Tomography) is projected to hold a dominant share of the market owing to its wide applications in oncology, cardiology and neurology. The increasing adoption of PET/CT (Positron Emission Tomography/Computed Tomography) for cancer diagnosis and treatment planning is anticipated to drive the growth of this modality. SPECT (Single-Photon Emission Computed Tomography) is another important modality in the Radiopharmaceutical Theranostics Market.It is commonly used in nuclear medicine procedures such as bone scans, myocardial perfusion imaging, and thyroid imaging. The growing demand for SPECT/CT (Single-Photon Emission Computed Tomography/Computed Tomography) systems, which combine the capabilities of SPECT and CT, is expected to contribute to the growth of this segment. Overall, the Modality segment of the Global Radiopharmaceutical Theranostics Market is poised for robust growth, driven by the increasing prevalence of chronic diseases, technological advancements, and the growing demand for personalized medicine. ### **Radiopharmaceutical Theranostics Market Target Disease Insights** Cancer, cardiovascular disease, neurological disorders, and endocrine disorders are the major diseases targeted by radiopharmaceutical theranostics. Cancer is the leading target disease for radiopharmaceutical theranostics, accounting for a significant share of the global market. In 2023, the market for cancer radiopharmaceutical theranostics was valued at USD 5.21 billion and is projected to reach USD 13.85 billion by 2032, growing at a CAGR of 12.3%. The growth is attributed to the rising incidence of cancer, the increasing adoption of personalized medicine, and the development of novel radiopharmaceutical theranostics.Cardiovascular disease is another major target disease for radiopharmaceutical theranostics, with a market size of USD 2.45 billion in 2023 and is projected to reach USD 6.52 billion by 2032, growing at a CAGR of 11.9%. The growth is attributed to the increasing prevalence of cardiovascular disease, the rising demand for non-invasive diagnostic techniques, and the development of new radiopharmaceutical theranostics for cardiovascular diseases. Neurological disorders and endocrine disorders are also significant target diseases for radiopharmaceutical theranostics, with growing markets driven by the increasing prevalence of these diseases and the need for improved diagnostic and therapeutic approaches. ### **Radiopharmaceutical Theranostics Market Regional Insights** The regional segment is a crucial aspect of the Global Radiopharmaceutical Theranostics Market, offering valuable insights into the market's geographical distribution and growth dynamics. North America leads the market with a significant share, driven by advanced healthcare infrastructure, high adoption of theranostics, and robust research and development activities. Europe follows closely, with a well-established healthcare system and a strong focus on personalized medicine. APAC is projected to witness substantial growth in the coming years, owing to rising healthcare expenditure, increasing awareness of theranostics and government initiatives to improve healthcare access.South America and MEA are expected to contribute to the overall market growth, albeit at a moderate pace, as these regions continue to develop their healthcare systems and invest in theranostic technologies. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Radiopharmaceutical Theranostics Market Key Players And Competitive Insights:** In the Radiopharmaceutical Theranostics Market industry, major players have been consistently putting efforts into developing products that can image and treat the cancerous cells of the body. The developed products are aligned to decrease the overall dosage of patients as well as to increase the treatment efficiency. The market is gaining attraction among the target users due to the adoption of new technologies, methods, and approaches to fulfill the unmet needs of the International Journal 2019 patients. The leading players in the Radiopharmaceutical Theranostics Market industry are substantially making investments in the research and development of new products, growing their presence across different regions, and gaining a competitive advantage. The importance of the regulatory bodies and government initiatives is substantially rising which is aligned with providing the appropriate guidelines and motivation for developing and commercializing the Radiopharmaceutical Theranostics Market products. The competitive landscape of the market is also getting fueled up with the new development.Cardinal Health is a world leader that provides products, services, and solutions in the healthcare industry. The company is based in Dublin, Ireland and there are 150 countries where it serves its clients. The comprehensive product portfolio and the distribution network of the company are applied to serve the various stakeholders of the healthcare industry, such as hospitals, clinics, pharmacies, and manufacturers as well as to the customers and patients. The company substantially focuses on innovation and technological advancements, which play a crucial role in enhancing the offering of the company. A detailed analysis states that Cardinal Health is substantially participating in the Radiopharmaceutical Theranostics Market industry by providing various radiopharmaceuticals and related services. The timely and accurate delivery of the products across the healthcare industry is ensured by the distribution network of the company.IBA MolecularIBA Molecular is a worldwide participant in the Radiopharmaceutical Theranostics Market industry. The company is largely focused on the development and production of medical imaging and therapy radiopharmaceuticals. The multi-modality imaging and therapy products and the services of the company meet the needs of thousands of patients every day. The research and development facilities of the company are used to offer the widest range of imaging and therapeutic solutions to patients. Involvements of the leading experts in the industry help to bring advanced products to the market. A similar approach is adopted in the case of Radiopharmaceutical Theranostics Market products. ### **Key Companies in the Radiopharmaceutical Theranostics Market Include:** - Toshiba Medical Systems - Nordion - Radiomedix - Lantheus Holdings - Mylan - Sirtex Medical - [Cardinal Health](https://www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/nuclear-medicine/radiopharmaceuticals/theranostics.html) - IBA - GE Healthcare - Merck KGaA - Philips Healthcare - Novartis - Bayer - Telix Pharmaceuticals ## **Radiopharmaceutical Theranostics Market Industry Developments** The global radiopharmaceutical theranostics market is expected to reach USD 26.71 billion by 2032, exhibiting a CAGR of 11.31% from 2024 to 2032. The increasing prevalence of chronic diseases, growing demand for personalized medicine, and technological advancements in radiopharmaceutical theranostics are driving market expansion. Asia Pacific is expected to witness significant growth due to rising healthcare expenditure and increasing awareness about theranostics. Recent news developments include Novartis' collaboration with Advanced Accelerator Applications to develop and commercialize 177Lu-PSMA-617 for prostate cancer treatment and Bayer's acquisition of Vividion Therapeutics to strengthen its oncology portfolio with targeted radiopharmaceuticals. ## **Radiopharmaceutical Theranostics Market Segmentation Insights** ### **Radiopharmaceutical Theranostics Market Application Outlook** - Oncology - Cardiology - Neurology - Endocrinology ### **Radiopharmaceutical Theranostics Market Radioisotope Outlook** - Fluorine-18 (18F) - Carbon-11 (11C) - Nitrogen-13 (13N) - Gallium-68 (68Ga) ### **Radiopharmaceutical Theranostics Market Modality Outlook** - PET (Positron Emission Tomography) - SPECT (Single-Photon Emission Computed Tomography) - SPECT/CT (Single-Photon Emission Computed Tomography/Computed Tomography) - PET/CT (Positron Emission Tomography/Computed Tomography) ### **Radiopharmaceutical Theranostics Market Target Disease Outlook** - Cancer - Cardiovascular Disease - Neurological Disorders - Endocrine Disorders ### **Radiopharmaceutical Theranostics Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### Rising Incidence of Cancer The increasing prevalence of cancer worldwide is a primary driver for the Radiopharmaceutical Theranostics Market. As cancer cases rise, the demand for effective diagnostic and therapeutic solutions intensifies. According to recent statistics, cancer is projected to affect millions annually, necessitating innovative treatment approaches.   Radiopharmaceuticals, which combine diagnostic imaging and targeted therapy, are gaining traction as they offer personalized treatment options. This trend is likely to continue, as healthcare providers seek to improve patient outcomes through precision medicine. The integration of radiopharmaceuticals in oncology is expected to enhance treatment efficacy, thereby propelling the growth of the market. ### Supportive Regulatory Frameworks Supportive regulatory environments are crucial for the advancement of the Radiopharmaceutical Theranostics Market. Regulatory agencies are increasingly recognizing the potential of radiopharmaceuticals in improving patient care and are streamlining approval processes for new products. This regulatory support encourages pharmaceutical companies to invest in research and development, leading to the introduction of innovative radiopharmaceuticals.   Additionally, favorable reimbursement policies for theranostic agents further stimulate market growth. As regulatory frameworks continue to evolve, they are expected to facilitate the entry of new players and products into the market, enhancing competition and innovation. ### Growing Demand for Personalized Medicine The shift towards personalized medicine is a significant factor propelling the Radiopharmaceutical Theranostics Market. Patients increasingly seek treatments tailored to their specific genetic profiles and disease characteristics. Radiopharmaceuticals, which allow for targeted therapy based on individual patient needs, align well with this trend.   The ability to customize treatment regimens enhances therapeutic outcomes and minimizes side effects, making radiopharmaceuticals an attractive option for healthcare providers. As the healthcare landscape evolves, the emphasis on personalized approaches is likely to drive further investment and innovation in the market, fostering growth and development. ### Increasing Investment in Healthcare Infrastructure The expansion of healthcare infrastructure is a vital driver for the Radiopharmaceutical Theranostics Market. As countries invest in modernizing healthcare facilities and technologies, the availability of advanced diagnostic and therapeutic options increases. Enhanced infrastructure supports the integration of radiopharmaceuticals into clinical practice, allowing for better patient access to these innovative treatments.   Moreover, investments in training healthcare professionals on the use of radiopharmaceuticals are essential for maximizing their potential. This growing focus on healthcare infrastructure is likely to create a conducive environment for the market, fostering growth and improving patient outcomes. ### Technological Advancements in Radiopharmaceuticals Technological innovations in the field of radiopharmaceuticals are significantly influencing the Radiopharmaceutical Theranostics Market. Advances in imaging technologies, such as PET and SPECT, have improved the accuracy of diagnostics, allowing for earlier detection of diseases. Furthermore, the development of novel radiotracers enhances the therapeutic efficacy of treatments.   The market is witnessing a surge in research and development activities aimed at creating more effective and safer radiopharmaceuticals. This technological evolution not only boosts the diagnostic capabilities but also expands the therapeutic applications of radiopharmaceuticals, thereby driving market growth. The continuous evolution of technology is expected to play a crucial role in shaping the future of the market. ## Future Outlook The Radiopharmaceutical Theranostics Market size is projected to reach USD 4.374 Billion by 2035, growing at a CAGR of 6.85%, driven by technological advancements, increasing cancer prevalence, and enhanced regulatory support. **New opportunities:** - Development of personalized radiopharmaceuticals for targeted therapies. Expansion of global distribution networks for radiopharmaceuticals. Investment in AI-driven diagnostic tools for improved patient outcomes. By 2035, the market is expected to achieve substantial growth, solidifying its role in precision medicine. ## Segment Insights ### By Application: Oncology (Largest) vs. Cardiology (Fastest-Growing) Oncology is the largest segment in the radiopharmaceutical theranostics market, accounting for a 58% share, driven by the increasing global incidence of cancer. This segment is driven by the rising demand for targeted therapy options that improve treatment outcomes and reduce side effects. Following oncology, cardiology is emerging as a fast-growing segment, spurred by advancements in radiopharmaceuticals that aid in the diagnosis and treatment of heart diseases. Healthcare providers are increasingly adopting these innovative solutions to enhance patient care. The growth trends in the radiopharmaceuticals market for these applications are influenced by technological advancements and a growing understanding of the molecular mechanisms underlying diseases. As more effective theranostics are developed, their adoption increases within oncology, while cardiology sees rapid uptake due to a rising prevalence of [cardiovascular](https://www.marketresearchfuture.com/reports/cardiovascular-devices-market-11859) diseases. The dual focus on personalized medicine in oncology and improved diagnostic capabilities in cardiology is steering the market towards significant expansion. Oncology (Dominant) vs. Neurology (Emerging) The [Oncology](https://www.marketresearchfuture.com/reports/oncology-drugs-market-12355) stands as the dominant segment in the market, primarily due to its extensive range of applications in cancer diagnosis and treatment. This segment utilizes targeted radiopharmaceuticals to enhance the precision of cancer therapies, leading to better patient outcomes and reduced side effects. In contrast, neurology is an emerging segment, fueled by a growing interest in diagnosing and treating neurological disorders with theranostic approaches. Neurology's development is marked by the introduction of advanced imaging agents that assist in conditions like Alzheimer's and epilepsy, where traditional diagnostic methods often fall short. While oncology remains the primary focus for many companies, the promise of neurology as a viable therapeutic area presents exciting opportunities for future market expansion. ### By Radioisotope: Fluorine-18 (Largest) vs. Gallium-68 (Fastest-Growing) Fluorine-18 (18F) holds the largest share in the radiopharmaceutical theranostics market at 46%, renowned for its critical role in PET imaging. Meanwhile, Gallium-68 (68Ga) is emerging as a key player, gaining traction due to its favorable characteristics for targeted therapies. Carbon-11 (11C) and Nitrogen-13 (13N) are also significant; however, they lag behind in terms of market share. The distribution indicates a clear preference for the versatility and efficiency of Fluorine-18 while demonstrating growing interest in Gallium-68 among healthcare providers. Radiopharmaceuticals: Fluorine-18 (Dominant) vs. Gallium-68 (Emerging) Fluorine-18 (18F) is still the dominant isotope in the radiopharmaceutical sector, primarily used in diagnostic imaging due to its optimal half-life and imaging capabilities. Its established presence in the market reflects its reliability and utility in detecting various conditions, particularly cancers. In contrast, Gallium-68 (68Ga) is rapidly emerging as a preferred choice for theranostic applications, particularly in targeted radiotherapy. This growth is attributed to advancements in radiolabeling technologies and the increasing preference for personalized medicine. Together, these isotopes define a significant portion of the market, with driven innovation bringing new activities forward. ### By Modality: PET (Largest) vs. SPECT (Fastest-Growing) In the Radiopharmaceutical Theranostics Market, the modality distribution showcases PET as the dominant segment, accounting for a 52% share due to its extensive applications in oncology and cardiology. SPECT follows, representing a significant share as well, while SPECT/CT and PET/CT modalities are gaining traction for their hybrid imaging capabilities. Each modality offers unique advantages, contributing to the overall diversity in imaging options available to clinicians and researchers, thereby fulfilling specific diagnostic needs across various therapeutic areas. Modality: PET (Dominant) vs. SPECT (Emerging) PET is recognized as the dominant modality in the market, especially noted for its high sensitivity and specificity in detecting malignancies. It utilizes short-lived isotopes which create real-time imaging capabilities, making it crucial for early diagnosis and ongoing monitoring. In comparison, SPECT is emerging rapidly, driven by advances in detector technology and increased adoption in clinical practice. SPECT offers cost-effectiveness and versatile applications, particularly in cardiology and neurology, thus capturing the interest of healthcare providers. As both modalities evolve with technological innovations, they position themselves strategically within the market, catering to the varied diagnostic requirements and improving patient outcomes. ### By Target Disease: Cancer (Largest) vs. Cardiovascular Disease (Fastest-Growing) In the Radiopharmaceutical Theranostics Market, cancer represents the largest segment, commanding a significant 60% share due to its high prevalence and the increasing focus on personalized medicine. Following closely, Cardiovascular Disease is emerging as a prominent segment, influenced by rising awareness and innovation in targeted therapies. Neurological Disorders and Endocrine Disorders, while important, currently hold smaller market shares relative to these leading segments. Cancer (Dominant) vs. Cardiovascular Disease (Emerging) Cancer continues to be the dominant focus in the market, driven by advancements in diagnostic and therapeutic technologies that allow for more precise treatment options. This segment benefits from extensive research funding and a robust pipeline of clinical trials aimed at enhancing the effectiveness of radiopharmaceuticals in managing various types of cancer. On the other hand, Cardiovascular Disease is considered an emerging segment, showing rapid growth due to a surge in the incidence of these conditions and the demand for innovative treatment solutions. As healthcare providers increasingly recognize the importance of early diagnosis and personalized therapies, investment in cardiovascular theranostics is expected to expand, thereby attracting more patients and healthcare initiatives into this sector. ## Regional Market Share Analysis ### North America : Leading Innovation and Adoption North America leads in the Radiopharmaceutical Theranostics Market size, accounting for over 45% of the global revenue in 2024. The region benefits from advanced healthcare infrastructure, significant investments in research and development, and a growing prevalence of cancer, which drives demand for targeted therapies. Regulatory support from agencies like the FDA further catalyzes market growth, ensuring rapid approval of innovative therapies. - CDC reports over 1.9 million new cancer cases annually in the U.S., with approximately 609,000 deaths per year. Additionally, NIH invests more than USD 7 billion annually in cancer research, accelerating innovation and supporting rapid adoption of advanced theranostic technologies across North America. The United States is the primary contributor, with key players such as Lantheus Medical Imaging and GE Healthcare leading the charge. Canada also plays a significant role, focusing on enhancing its healthcare capabilities. The competitive landscape is characterized by collaborations and partnerships among major companies, ensuring a steady pipeline of innovative products to meet the rising demand for personalized medicine. ### Europe : Emerging Regulatory Frameworks Europe Radiopharmaceutical Theranostics Market size was valued at USD 0.633 billion in 2024, making it the second-largest regional market with a 30% share. The region is witnessing a surge in demand due to increasing cancer incidences and a robust regulatory framework that supports the development of novel therapies. The European Medicines Agency (EMA) plays a crucial role in facilitating market entry for innovative products, thereby enhancing patient access to advanced treatments. - ECDC reports around 1.3 million cancer deaths annually in Europe, while WHO estimates nearly 3.7 million new cancer cases each year across the region. Strong regulatory frameworks and rising healthcare investments are enabling faster access to innovative radiopharmaceutical therapies. Leading countries include Germany, France, and the UK, where significant investments in healthcare technology are evident. Major players like Bayer and Siemens Healthineers are actively involved in research and development, contributing to a competitive landscape that fosters innovation. The presence of established healthcare systems and a focus on personalized medicine further bolster the market's growth potential. ### Asia-Pacific : Rapidly Growing Market Potential Asia-Pacific is rapidly emerging as a significant player in the radiopharmaceutical theranostics market, holding approximately 20% of the global market share. The region's growth is driven by increasing healthcare expenditure, rising awareness of advanced diagnostic techniques, and a growing patient population. Countries like China and India are investing heavily in healthcare infrastructure, which is expected to further boost market demand in the coming years. China is leading the charge, with substantial investments in research and development, while India is focusing on enhancing its manufacturing capabilities. The competitive landscape is evolving, with both local and international players, including Telix Pharmaceuticals and Bracco Imaging, striving to capture market share. The region's diverse healthcare needs present unique opportunities for innovation and growth in theranostics. ### Middle East and Africa : Untapped Market Opportunities The Middle East and Africa region is gradually emerging in the radiopharmaceutical theranostics market, currently holding about 5% of the global market share. The growth is primarily driven by increasing investments in healthcare infrastructure and a rising prevalence of chronic diseases. Governments are focusing on enhancing healthcare access and quality, which is expected to catalyze market growth in the coming years. Countries like South Africa and the UAE are leading the way, with initiatives aimed at improving diagnostic capabilities. The competitive landscape is still developing, with both local and international players exploring opportunities. Key players are beginning to establish a presence in the region, indicating a growing interest in the potential of theranostics to address healthcare challenges. ## Competitive Benchmarking The Radiopharmaceutical Theranostics Market is currently characterized by a dynamic competitive landscape, driven by advancements in precision medicine and the increasing demand for targeted therapies. Key players such as Novartis (CH), Bayer (DE), and Lantheus Medical Imaging (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Novartis (CH) has focused on innovation through the development of novel radiopharmaceuticals, while Bayer (DE) emphasizes strategic partnerships to expand its product offerings.   Lantheus Medical Imaging (US) is leveraging its expertise in imaging technologies to enhance its theranostic capabilities, thereby shaping a competitive environment that prioritizes innovation and collaboration. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Siemens Healthineers (DE) and GE Healthcare (GB) suggests a trend towards consolidation, as these firms seek to leverage their extensive resources and technological capabilities to gain a competitive edge.    In August 2025, Novartis (CH) announced a strategic collaboration with a leading biotechnology firm to develop a new class of radiopharmaceuticals aimed at treating specific cancer types. This partnership is expected to accelerate the development timeline and enhance the therapeutic efficacy of their offerings, positioning Novartis as a leader in the theranostics space. The collaboration underscores the importance of innovation and strategic alliances in driving growth within the market.    In September 2025, Bayer (DE) launched a new radiopharmaceutical product designed for personalized treatment of prostate cancer, which is anticipated to significantly improve patient outcomes. This product launch not only reflects Bayer's commitment to addressing unmet medical needs but also highlights the company's strategy of integrating advanced technologies into its product development processes. Such initiatives are likely to strengthen Bayer's competitive position in the theranostics market.    In October 2025, Lantheus Medical Imaging (US) expanded its manufacturing capabilities by investing in a state-of-the-art facility dedicated to the production of radiopharmaceuticals. This investment is expected to enhance supply chain reliability and meet the growing demand for theranostic agents. By bolstering its manufacturing infrastructure, Lantheus is positioning itself to respond more effectively to market needs, thereby reinforcing its competitive stance.    As of October 2025, the competitive trends in the Radiopharmaceutical Theranostics Market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming pivotal in shaping the landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains, thereby redefining the parameters of success in this burgeoning market. ## Recent News & Developments **DEC 2025:** Radiopharmaceutical theranostics is emerging as one of the fastest-growing segments in precision oncology. Recent approvals of targeted radioligand therapies have significantly expanded clinical use for cancers such as prostate and neuroendocrine tumors. Major companies are investing heavily in isotope production and next-generation radionuclide therapies to meet escalating demand. Collaboration between imaging and therapy developers is strengthening, establishing theranostics as a central pillar of future cancer-care strategies. The global radiopharmaceutical theranostics market is expected to reach USD 26.71 billion by 2032, exhibiting a CAGR of 11.31% from 2024 to 2032. The increasing prevalence of chronic diseases, growing demand for personalized medicine, and technological advancements in radiopharmaceutical theranostics are driving market expansion. Asia Pacific is expected to witness significant growth due to rising healthcare expenditure and increasing awareness about theranostics. Recent news developments include Novartis' collaboration with Advanced Accelerator Applications to develop and commercialize 177Lu-PSMA-617 for prostate cancer treatment and Bayer's acquisition of Vividion Therapeutics to strengthen its oncology portfolio with targeted radiopharmaceuticals. ## Report Scope | MARKET SIZE 2024 | 2.11(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 2.255(USD Billion) | | MARKET SIZE 2035 | 4.374(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.85% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Novartis (CH), Bayer (DE), GE Healthcare (GB), Siemens Healthineers (DE), Lantheus Medical Imaging (US), Bracco Imaging (IT), Elekta (SE), Telix Pharmaceuticals (AU), Iradimed Corporation (US) | | Segments Covered | Applications, Radioisotope, Modality, Target Disease, Regional | | Key Market Opportunities | Integration of artificial intelligence in Radiopharmaceutical Theranostics enhances personalized treatment approaches and diagnostic accuracy. | | Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Radiopharmaceutical Theranostics Market as of 2024?** A: The market valuation was 2.11 USD Billion in 2024. **Q: What is the projected market size for the Radiopharmaceutical Theranostics Market by 2035?** A: The projected valuation for 2035 is 4.374 USD Billion. **Q: What is the expected CAGR for the market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 6.85%. **Q: Which application segments are driving growth in the Radiopharmaceutical Theranostics Market?** A: Key application segments include Oncology, Cardiology, Neurology, and Endocrinology, with Oncology valued at 1.95 USD Billion by 2035. **Q: What are the leading radioisotopes used in the market?** A: Fluorine-18 (18F) and Gallium-68 (68Ga) are prominent, with 18F projected to reach 1.75 USD Billion by 2035. **Q: How do the modalities of imaging impact the Radiopharmaceutical Theranostics Market?** A: PET and SPECT modalities are crucial, with PET expected to grow to 1.75 USD Billion by 2035. **Q: Who are the key players in the Radiopharmaceutical Theranostics Market?** A: Notable players include Novartis, Bayer, GE Healthcare, and Siemens Healthineers. **Q: What target diseases are primarily addressed by the market?** A: The market focuses on Cancer, Cardiovascular Disease, Neurological Disorders, and Endocrine Disorders, with Cancer projected to reach 2.0 USD Billion by 2035. **Q: How does the market compare across different regions?** A: While specific regional data is not provided, the overall growth trajectory suggests increasing investments in North America and Europe. **Q: What trends are influencing the future of the Radiopharmaceutical Theranostics Market?** A: Trends include advancements in imaging technologies and increasing demand for personalized medicine, likely enhancing market growth. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/radiopharmaceutical-theranostics-market-27107*